Evotec stock: RBC halves target before November 5 results

Published on 11/02/2026 at 17:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock faces a wide split in analyst expectations before its November 5 results. RBC cut its target but kept an Outperform rating.

Analyst views split before November results

RBC Capital Markets cut its price target while retaining an Outperform rating.
Evotec's second-quarter revenue declined year on year and the quarterly loss per share widened.
The company is scheduled to release nine-month results and provide a business update on November 5.

Evotec SE, DE0005664809, Illustration mit AI erstellt.

Evotec stock traded at 2.81 euros on Lang & Schwarz at 17:49 CET on Monday, November 2, 2026.

A November 2 analysis by AD HOC NEWS highlights a sharp gap between Evotec's analyst recommendations and their valuation assumptions. Four analysts are listed with buy ratings and two with hold ratings, but RBC Capital Markets cut its price target to 5 euros from 10 euros while retaining its Outperform rating.

Target cuts reshape the debate

The unchanged rating and lower target point to a distinction investors should keep in view: an analyst can remain positive on the direction of the business while reducing the price level considered achievable. The analysis also notes that RBC attached a speculative qualification to its stance.

Operating figures provide the backdrop. Evotec's second-quarter 2026 revenue came to 143.48 million euros, down 16.21 percent from the prior-year period. Loss per share widened to 0.26 euros from 0.24 euros. Those figures are reported results, while the analyst targets are forward-looking assessments.

November 5 is the next checkpoint

Evotec is scheduled to publish results for the first nine months of 2026 on Thursday, November 5, together with a business update. The English-language webcast and conference call are scheduled to start at 2:00 pm CET. Investors will be looking for confirmation of the preliminary performance and further detail on the path toward the full-year outlook.

JPMorgan disclosed a combined position of 6.54 percent, including shares and instruments, while Goldman Sachs disclosed 13.51 percent, largely through instruments. These voting-rights disclosures describe the structure of reported positions, not a direct assessment of Evotec's operating performance.

For a real-time quote of Evotec stock, investors should monitor the next scheduled company update.

Market sentiment for German equities remains relevant as investors assess upcoming company results through the DAX market focus.

See More news and analyses on Evotec stock.